Logo do repositório
 
Publicação

Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease : a systematic review and meta-analysis

2013-09Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorCosta, João
dc.contributor.authorMagro, Fernando
dc.contributor.authorCaldeira, Daniel
dc.contributor.authorAlarcão, Joana
dc.contributor.authorSousa, Rita
dc.contributor.authorCarneiro, António Vaz
dc.date.accessioned2018-04-16T11:06:47Z
dc.date.available2018-04-16T11:06:47Z
dc.date.issued2013-09
dc.descriptionCopyright © 2013 Crohn’s & Colitis Foundation of America, Inc.pt_PT
dc.description.abstractBackground: We systematically reviewed infliximab benefit in reducing hospitalizations and/or major surgery rates in patients with inflammatory bowel disease (IBD). Methods: A literature search to May 2012 was performed to identify all studies (experimental and observational) evaluating patients with IBD treated with infliximab and providing data on hospitalizations and/or major surgery rates. Three reviewers independently performed studies' selection, quality assessment, and data extraction. Analyses were carried according to study design (randomized clinical trials [RCTs] and observational studies) and IBD type (Crohn's disease [CD] and ulcerative colitis [UC]). Random-effects meta-analysis was used to derive pooled and 95% confidence intervals (CIs) estimates of odds ratios (OR). Heterogeneity was assessed with I2 test. Results: Twenty-seven eligible studies were included (9 RCTs and 18 observational studies). Infliximab reduced hospitalization risk, both in pooled RCTs (OR, 0.51; 95% CI 0.40-0.65; I2 = 0%) and results of observational studies (OR, 0.29, 95% CI, 0.19-0.43; I2 = 87%), without differences between CD and UC. Infliximab reduced surgery risk in pooled RCTs results, both in CD (OR, 0.31; 95% CI, 0.15-0.64; I2 = 0%) and UC (OR, 0.57; 95% CI, 0.37-0.88; I2 = 0%). Pooled estimate from observational studies favored infliximab for patients with CD (OR, 0.32; 95% CI, 0.21-0.49; I2 = 77%), but not for patients with UC. Conclusions: The best evidence available points toward a reduction of the risk of hospitalization and major surgery requirement in patients with IBD treated with infliximab. This impact is clinically and economically relevant because hospitalization and surgery are considered to be markers of disease severity and significantly contribute to the total direct costs associated with IBD.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citation(Inflamm Bowel Dis 2013;19:2098–2110pt_PT
dc.identifier.doi10.1097/MIB.0b013e31829936c2pt_PT
dc.identifier.issn1078-0998
dc.identifier.urihttp://hdl.handle.net/10451/32796
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.relation.publisherversionhttps://academic.oup.com/ibdjournal/article-abstract/19/10/2098/4602993?redirectedFrom=fulltextpt_PT
dc.subjectSystematic reviewpt_PT
dc.subjectMeta-analysispt_PT
dc.subjectBiologic therapiespt_PT
dc.subjectInflammatory bowel diseasept_PT
dc.subjectHospitalizationpt_PT
dc.subjectSurgical procedures, operativept_PT
dc.titleInfliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease : a systematic review and meta-analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2110pt_PT
oaire.citation.issue10pt_PT
oaire.citation.startPage2098pt_PT
oaire.citation.titleInflammatory Bowel Diseasespt_PT
oaire.citation.volume19pt_PT
person.familyNameCosta
person.familyNameCaldeira
person.familyNameVaz Carneiro
person.givenNameJoão
person.givenNameDaniel
person.givenNameAntónio
person.identifier480560
person.identifier.ciencia-idAA19-EC35-8D01
person.identifier.orcid0000-0002-5831-4921
person.identifier.orcid0000-0002-2520-5673
person.identifier.orcid0000-0002-2783-0544
person.identifier.ridL-8026-2013
person.identifier.scopus-author-id55499748300
person.identifier.scopus-author-id36623384200
person.identifier.scopus-author-id7006837792
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication0924f405-2d3a-4914-9097-24aa639bd97f
relation.isAuthorOfPublicationeba36bb8-5eb3-4ccc-88f8-bd7012d42382
relation.isAuthorOfPublication376d157f-1127-4663-9d99-038dac28f37d
relation.isAuthorOfPublication.latestForDiscovery0924f405-2d3a-4914-9097-24aa639bd97f

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Infliximab.pdf
Tamanho:
490.81 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM-CEMBE-Artigos em Revistas Internacionais